A coming of age for personalised medicine?
This article was originally published in Clinica
Executive Summary
The recent agreement between UK diagnostics company Enigma Diagnostics and GlaxoSmithKline to commercialise a rapid point-of-care test for different strains of influenza is the latest in a series of deals that underline the growing importance of so-called companion diagnostics. It is now widely expected that this category of diagnostics will have a big influence on healthcare and the future shape of the pharma and diagnostics markets.